Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Antidepressant Medications Clear all
Completed Phase 4 Interventional Results available

Advancing Personalized Antidepressant Treatment Using PET/MRI

NCT02623205
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Sequenced Treatment Effectiveness for Posttraumatic Stress

NCT04597190
View directory record Official record
Conditions
PTSD
Interventions
Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Written Exposure Therapy
Drug · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
North Little Rock, Arkansas • West Memphis, Arkansas • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

TRIAD - Treatment of Insomnia and Depression

NCT00767624
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Antidepressant, Desensitization Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Stanford, California • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Predictors of Antidepressant Response

NCT02178696
View directory record Official record
Conditions
Depression
Interventions
Placebo, identified as placebo to participants, Celexa or other antidepressant as clinically indicated, Placebo, identifed to participants as "Active medication"
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Not applicable Interventional Results available

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

NCT01993017
View directory record Official record
Conditions
Acute Coronary Syndrome, Depressive Symptoms
Interventions
Cognitive Behavioral Therapy (CBT), Antidepressant Medication, Standard Care, Depressive symptom screener, No intervention
Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
1,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Bloomington, Minnesota • New York, New York • Henderson, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

NCT04560660
View directory record Official record
Conditions
PTSD
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 7:30 PM EDT
Recruiting Not applicable Interventional

The Treatment of Painful Diabetic Neuropathy With Diet

NCT07509671
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Peripheral Neuropathy With Type 2 Diabetes, Vegan Diet
Interventions
Diet, Medical management
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Hendersonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression

NCT00824044
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Escitalopram
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 2 Interventional

Exercise Plus Duloxetine for Knee Osteoarthritis

NCT04111627
View directory record Official record
Conditions
Knee Osteoarthritis, Depression
Interventions
Aerobic exercise, Duloxetine
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

NCT02972632
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Costa Mesa, California • Culver City, California • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 10, 2026, 7:30 PM EDT
Withdrawn Phase 2 Interventional

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

NCT03290963
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Lithium, Placebo, Ketamine
Drug
Lead sponsor
William V. Bobo, M.D.
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional

Thyroid Medication and Antidepressants for Treating Major Depression

NCT00208702
View directory record Official record
Conditions
Major Depression
Interventions
Triiodothyronine, Placebo, Sertraline
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Contact: Developing New Clinical Management Strategies

NCT03812588
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Not applicable Interventional Results available

Trial of Collaborative Depression Care Management for HIV Patients

NCT01372605
View directory record Official record
Conditions
Depression, HIV
Interventions
Measurement-Based Care collaborative depression management, Enhanced Usual Care
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

NCT01537068
View directory record Official record
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Interventions
Desvenlafaxine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT03968159
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Not applicable Interventional

Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices

NCT02015806
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy
Interventions
RxTimerCap, Take-N-Slide, Pillbox
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
53,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Woonsocket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 1 Interventional Results available

Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression

NCT00356304
View directory record Official record
Conditions
Depression
Interventions
Motivational interviewing, Treatment as usual
Behavioral
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Treating Hearing Loss to Improve Mood and Cognition in Older Adults

NCT03321006
View directory record Official record
Conditions
Hearing Loss, Depression
Interventions
Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 10, 2026, 7:30 PM EDT
Completed Early Phase 1 Interventional

SSRIs vs. TCAs for Depression in ALS Patients

NCT02851914
View directory record Official record
Conditions
Depression, Amyotrophic Lateral Sclerosis
Interventions
Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI")
Drug
Lead sponsor
St. Louis University
Other
Eligibility
25 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 10, 2026, 7:30 PM EDT